{
    "id": 5588,
    "name": "lung papillary adenocarcinoma",
    "source": "DOID",
    "definition": "A papillary adenocarcinoma that is located_in the lung. [url:https\\://radiopaedia.org/articles/mediastinal-teratoma, url:https\\://www.ncbi.nlm.nih.gov/pubmed/26766978]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:5588",
    "evidence": [
        {
            "id": 9256,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung papillary adenocarcinoma cell line harboring EGFR wild-type and expressing PAK1 demonstrated resistance to Iressa (gefitinib) in culture (PMID: 27178741).",
            "molecularProfile": {
                "id": 26797,
                "profileName": "EGFR wild-type PAK1 pos"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 5588,
                "name": "lung papillary adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9978,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with ABBV-399 resulted in complete response in a MET-over expressing papillary lung adenocarcinoma cell line xenograft model (PMID: 27573171).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 1363,
                "therapyName": "Telisotuzumab vedotin",
                "synonyms": null
            },
            "indication": {
                "id": 5588,
                "name": "lung papillary adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7833,
                    "pubMedId": 27573171,
                    "title": "ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27573171"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        
    ]
}